GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout

Revenues Up By 32%

 
• By Andrew McConaghie

GlaxoSmithKline has just acquired a late-stage oncology asset, and sales of Shingrix are on the up again, but the outcome of its RSV vaccine study remains the main focus for 2022.

GSK Skyline
GlaxoSmithKline will spin out its consumer health division in July - by which time its RSV vaccine results should also be ready. • Source: Alamy

More from Business

More from Scrip